A team of researchers from Baylor College of Medicine and international collaborators found that metformin targets a small protein in the ventromedial hypothalamus (VMH), a part of the brain that helps regulate energy and blood sugar levels.
The protein, called Rap1, is crucial for metformin’s action. When metformin suppresses Rap1 activity, it causes special nerve cells in the VMH to become more active, helping to lower blood sugar.
To test this, the research team used lab mice engineered to lack Rap1 in their VMH. These mice did not respond to metformin, showing that Rap1’s presence is necessary for the drug to function properly. The findings suggest that metformin works not only by acting on the liver and gut but also through direct action in the brain.
Further experiments were conducted where metformin was delivered directly into the brains of diabetic mice. Even though the doses were much smaller than the oral doses typically used, the mice still showed significant reductions in blood sugar. This experiment confirms that the drug’s effects are not limited to peripheral organs but also directly involve the brain’s regulation of blood sugar.
The research also showed that metformin activates SF1 neurons in the VMH, which are essential for blood sugar control. Without Rap1, these neurons did not respond to the drug, further reinforcing the idea that this brain pathway is critical to metformin’s function.
This discovery is a game-changer in diabetes research. It not only alters our understanding of how metformin works but also opens the door to developing new treatments that target brain pathways for better blood sugar control. The study also raises questions about the drug’s potential impact on brain aging and overall brain health, offering exciting possibilities for future research.
With this new insight, scientists are now exploring how metformin’s action in the brain could lead to more effective treatments for diabetes and other related health conditions.
Leave a Reply